Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer

摘要

Tumor mutational burden (TMB) has emerged as a biomarker for response to immune checkpoint blockade in clinical trials. We broadened the potential impact of TMB by evaluating the utility of commercial comprehensive genomic profiling in non small-cell lung cancer in clinical practice. We analyzed 72 patients and 34 treated with anti programmed cell death 1/programmed death ligand 1 therapy, with higher TMB predicting longer overall survival.